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5-ﬂuorouracil (5-FU) is widely used in chemotherapy for gastric and colorectal cancer, but gemcitabine (GEM), and not 5-FU, is
approved as a standard drug for use in pancreatic cancer. Interindividual variation in the enzyme activity of the GEM metabolic
pathway can aﬀect the extent of GEM metabolism and the eﬃcacy of GEM chemotherapy. Human equilibrative nucleoside
transporter 1 (hENT1) is recognized as a major transporter of GEM into cells. In addition, a factor that activates hENT1 is
the inhibition of thymidylate synthase (TS), one of the 5-FU metabolic enzymes; TS inhibition mediates depleting intracellular
nucleotide pools, resulting in the activation of the salvage pathway mediated through hENT1. In this paper, the role of 5-FU in
GEM-based chemotherapy for pancreatic cancer is discussed with special emphasis on enzymes involved in the 5-FU and GEM
metabolicpathwaysandin thecorrelation between GEM responsiveness andtheexpression of5-FU andGEM metabolic enzymes.
1.Introduction
Pancreatic cancer is one of the most life-threatening cancers;
35,240 deaths in Americans in 2009 (6% of all United States
cancer deaths) make this cancer one of the leading causes of
cancer-related death [1]. In spite of recent progress in surgi-
cal procedures, the operative resectability rate of pancreatic
cancer remains unsatisfactory at 9% to 20% [2, 3]. Devel-
opment of chemotherapeutic modalities has shifted from 5-
ﬂuorouracil (5-FU), one of the primary standard drugs used
totreatsolidcancers,togemcitabine(GEM,Gemzar; EliLilly
andCompany, Indianapolis, Ind),themost anticipatedagent
for the treatment of this problematic disease [4]. However,
treatment results and favorable outcomes with GEM remain
variable; the response rate with GEM ranges from 5.4%
to 16.7% [5, 6], and the median survival time (MST) of
patients treated with 5FU of 4.2–4.5 months [5]i se x t e n d e d
by GEM to 5.9–6.5 months [4, 6]. The concept of single-
agent chemotherapy is clearly limited, and novel approaches
to combination therapy should be considered. Here, we
describe our recent challenges in pancreatic cancer and
review the chemotherapeutic procedures currently available
for the treatment of pancreatic cancer.
2.Applicationof Biological Studyto
PancreaticCancerTherapy
Recently, the study of the cell signaling pathway has been
applied to the control of cancer proliferation, invasion,
and metastasis as a molecular targeted therapy [7]. Among
them, vitamin K3(menadione), which inducescell apoptosis
through activation of oxidative stress, has also been expected
as a unique anticancer drug for pancreatic cancer [8, 9].
In the process of bringing experimental studies of such
agents to the clinical trial stage, a drug delivery system
is currently under consideration [10]. In parallel with the
developmentofthesefuturebiochemicaltrials, recentstudies
based on standard chemotherapy with GEM, have also been
developed.
Nucleosidetransporters are commonlyknown toinclude
two equilibrative nucleoside transporters (ENT1/2) and
three concentrative nucleoside transporters (CNT1/2/3)
[11]. Recent kinetic studies of human cell lines have shown
the intercellular uptake of GEM to depend mainly on ENT1,
which localizes in plasma and mitochondrial membranes
[11–13]. ENT1 activity was reported to be a prerequisite
for the occurrence of the growth inhibitory eﬀect of GEM,2 ISRN Oncology
because cells deﬁcient in ENT1 activity were highly resistant
to GEM; the rate of growth inhibition was increased 39- to
1800-foldinthepresenceofENT1[12].ExpressionofmRNA
and proteins was also evaluated as a favorable predictor of
the eﬀect of GEM clinically; MST was longer in patients
with high versus low expression, 25.7 versus 8.5 months
with mRNA expression (P = .001), and 13.0 versus 4.0
months with protein expression (P = .01) [14, 15]. These
results suggest the action of ENT1 to be critical for GEM
metabolism.
Intracellular enzymes deoxycytidine kinase (dCK), ribo-
nucleotide reductase (RR), and 5 -nucleotidase (5 -NT) are
alsoreported tobeimportant intheconversionofGEM toits
inactive form[16].Somestudiesemphasizing theﬁrst stepin
limiting GEM phosphorylation by overexpression of dCK in
tumorcellsdeﬁcientintheenzymehaveshown restorationof
the response to GEM [17, 18]. RR is essential for DNA poly-
merization/repair [19] and consists of large and small dimer-
ized subunits, M1 and M2, respectively. The M1 subunit
possesses a binding site for enzyme regulation (regulatory
subunit), and the M2 subunit is involved with RR activity
(catalyticsubunit)[20,21].Because5 -NTreducesphospho-
rylated metabolitesofGEM, theactivity levelof5 -NT might
also be a targetfor evaluationas theone factor most aﬀecting
the clinical outcome of GEM chemotherapy [22].
Although RRM1, dCK, and 5 -NT are useful predictors
of GEM resistance [23], the individual actions of each of
RR, dCK, and 5 -NT have not been reported as useful
predictors of prognosis in pancreatic cancer chemother-
apy. Namely, pancreatic cancer cells with a higher ratio
of hENT1×dCK/RRM1×RRM2 showed higher cytotoxicity,
and those cells with a lower ratio showed lower cytotoxicity
[21]. Further studies are necessary to conﬁrm the usefulness
of these three factors as predictors of prognosis in pancreatic
cancer.
3.The RoleofOne 5-FU MetabolicEnzyme,
ThymidylateSynthase
Thymidylate synthase (TS) is generally known to be
important in 5-FU metabolism [24, 25]. In solid-type
carcinomas, TS expression was estimated for its ability
to predict sensitivity to 5-FU; increase in the expression
of 5-FU mRNA/protein resulted in resistance to 5-FU in
colorectalcancer[26, 27]. Lowexpression ofTS, asevaluated
by immunohistochemistry and reverse-transcription PCR
(RT-PCR), correlated with a favorable response to 5-FU-
based therapy in colorectal cancer patients [25, 28, 29]. In
pancreatic cancer, however, survival rate was better in the
patientswithhighTSexpression[30].Incontrast,expression
of TS mRNA was found to correlate with patient survival;
survival was longer in patients with low expression, but in
patients with high TS expression, 5-FU-based chemotherapy
showed favorable results [31]. Taken together, TS expression
is related to 5-FU metabolism and its chemotherapeutic
eﬀect. In addition, Rauchwerger et al. previously reported
that 5-FU itself plays a role in the inhibition of TS, and
TS inhibitor modulates hENT1 [32]. On this basis, we
investigated methods to improve pancreatic cancer therapy.
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Figure 1: Cellular factor expression in several pancreatic cancer
cell lines. Cellular factor-related metabolism for 5-FU or GEM
was evaluated by Western blotting. Each value under the blotting
band was obtained from comparison with the level of mouse mon-
oclonal anti-beta-actin. hENT1, human equilibrative nucleoside
transporter 1; TS, thymidylate synthase.
4.Challengestothe Better Treatmentof
PancreaticCancer
Expressed levels of 5-FU and/or GEM-related metabolic
protein in seven independent pancreatic cancer cell lines
(PANC-1, MIAPaCa-2, BxPC-3, Hs766T, Capan-2, AsPC-
1 ,a n dC F P A C - 1 )w e r ec o m p a r e dw i t ht h eh a l fm a x i m a l
inhibitory concentrations (IC50s)of GEM or 5-FU, and only
TS expression was found to correlate positively with drug-
induced inhibitory eﬀect on cell growth (P = .0169) [33].
hENT1 expression was found to be similar for each of these
pancreatic cancercell lines, whereas TS expression was found
to be high in PANC-1, and moderate in MIAPaCa-2 and
l o wi nB x P C - 3 ,a ss h o w ni n( Figure 1). The relation between
TS expression and GEM resistance was demonstrated by
using these three pancreatic cancer cell lines (Figure 2).
The inhibition of TS expression due to 5-FU (0.1 or
1.0µM, doses having no cell-inhibitory or cell-death eﬀects)
was also shown to decrease GEM resistance in a dose-
dependent manner. The inhibition of TS due to siRNA
on PANC-1, which is the cell line most tolerant to GEM
and which shows the highest expression of TS protein, also
signiﬁcantly decreased the resistance of PANC-1 to GEM,
showing a decrease in IC50 from 77.0 ± 2.6nM to 7.7 ±
1.1nM (P = .0019). In addition, in our clinical study
of patients treated with GEM after surgery for pancreatic
cancer, low expression of TS protein evaluated in resected
specimens by immunohistochemical techniques was found
to correlate signiﬁcantly with prolongation of disease-free
survival (15.9 ± 12.4v e r s u s7 .0 ± 3.5m o n t h s ,P = .0256),
a ss h o w ni n( Figure 3).
From our experience with pancreatic cancer cell lines,
IC50s of 5-FU varied quite widely (9.0–1805.1µM), but the
IC50s of GEM were found to be stable (6.1–77.6nM); there-
fore, GEMhasbeenacceptedasaﬁrst-line chemotherapeutic
drug for the treatment of pancreatic cancer [4]. In contrast,
according to these studies, 5FU could be useful not only to
inhibit cell growth by its chemotherapeutic actions but also
to reduce TS expression to improve sensitivity to GEM.ISRN Oncology 3
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Figure 2: (a) Drug resistance of pancreatic cancer cells to 5-
FU+GEM. Cultured cells (5 × 103 cells/well) were exposed to
graded concentrations of gemcitabine (0, 10−2–104 nM) together
with several 5-FU concentrations (0, 0.1, 1.0µM) for 72 h. Drug
resistance was expressed as the concentration of drug that inhibited
colony formation by 50% (IC50). The control for each cell line (5-
FU, 0µM) showed statistical signiﬁcance with each of the same cell
lines (∗)( P<. 01). (b) Eﬀect of TS expression on GEM resistance.
Knockout of TS expression signiﬁcantly decreased resistance to
GEM in pancreatic cancer cells as evidenced by the detected change
in IC50s from 77.0 ± 2.6nMto7.7 ± 1.1nM. Results are expressed
as mean ± S D .B a r ,S D ;T S ,t h y m i d y l a t es y n t h a s e .
5.The BeneﬁtofCombinationTreatmentof
Gemwith5-FU
For GEM-induced intracellular changes, is hENT1 truly the
most important factor? Althougha previousreport indicated
that hENT1 is a useful predictor of GEM responsiveness
or MST of pancreatic cancer patients treated with GEM,
augmentation of hENT1 mRNA was detected after GEM
treatment in the cells, whereas DNA synthesis inhibitor
was found to increase the activity of some nucleoside
transporters at the cell surface [34]. Resistance to GEM
in pancreatic cancer cell lines does not appear to involve
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Figure 3: Comparison of patient disease-free survival rates. In
patients receiving GEM treatment after surgery (n = 13), disease-
free survival was compared according to percent of thymidylate
synthase(TS)proteinexpression.Monthsaftersurgery;mean ±SD.
hENT1; inhibition of hENT1-mediated transport in pancre-
atic cell lines modiﬁes GEM responsiveness either modestly
orn otatall[34].Inaddition,we havepreviouslyreported on
the contribution of TS to GEM chemotherapy [33]. Indeed,
a ss h o wni n(Figure 1),thediﬀerencesdetectedintheprotein
expression levels of TS (0.176–1.623), but not those of
hENT1 (0.781–1.114), correlated with GEM responsiveness,
suggesting that hENT1 itself has no closecorrelation toGEM
resistance.
In the metabolic pathway of GEM, not only GEM
metabolic enzymes but also TS has been shown to have
a direct or indirect correlation with GEM metabolism:
a TS inhibitor, such as 5-FU, in the de novo pathway
mediates depleting intracellular nucleotide pools, resulting
in activation of the salvage pathway and hENT1 as well [13,
35]( Figure 4). The process of activating hENT1 mediates
the diﬀusion of nucleosides, including those associated
with GEM, across plasma membranes in accordance with
the concentration gradient [32]. Then, because hENT1
represents as a main GEM transporter, lower expression of
TS might be related to transportation of GEM due to hENT1
activation. Accordingtoourexperiments, TSinhibitionitself
is quite critical in GEM-mediated cancer cell death and
also might be useful in GEM-resistant pancreatic cancer.
Decreasing protein expression of TS with 5-FU probably
induces a better prognosis for the patient undergoing GEM
chemotherapy.
6.FutureProspects
Although insuﬃcient antitumor eﬀect in pancreatic cancer
has been detected with 5-FU alone, its modulating action
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(dFdC)
TS inhibitors (5-FU, etc.)
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dFdCMP
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Cytotoxicity
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RR
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Figure 4: Contribution of thymidylate synthase (TS) in metabolic
pathway of gemcitabine. For explanation of symbols and metabolic
routes, see text. hENT1, human equilibrative nucleoside trans-
porter; dCK, deoxycytidine kinase; RR, ribonucleotide reductase;
5 -NT, 5 -nucleotidase; CDA, cytidine deaminase.
the mid-trial report of the GEMSAP trial (Phase II) for
Stage IV pancreatic cancer (Nakai et al.) in Japan revealed
that chemotherapy with GEM plus S-1 (oral 5-FU prodrug,
tegafur, gimeracil, and oteracil potassium) might be superior
to chemotherapy with GEM alone (median progression-free
survival, 5.4 versus 3.6 months, hazard ratio = 0.64 (95%
conﬁdence interval 0.42–0.97), P = .036; overall survival,
14.1 versus 8.7 months, P = .104) [36]. These experimental
clinicalresults were shown by ourrecent study and suggested
that TS and the dihydropyrimidine dehydrogenase (DPD)
inhibitory eﬀect of S-1 might produce additional eﬀect on
GEM [36]. In the future, the study of application timing
and dosing of 5-FU, and S-1, that induce the most favorable
outcome in regard to hENT1 should be continued. The
challenge to provide better treatment against advanced
pancreatic cancer is just beginning.
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